All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Asia EquityAsia IPOs

SciClone Pharma prices HK$2.2bn IPO at top end


SciClone Pharmaceuticals bagged HK$2.18bn ($281.2m) after pricing its IPO high on the back of storming demand from institutional and retail investors, according to sources close to the deal.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree